The Honest Dose #2

A few weeks in and I'm still a little surprised this is actually working. I built PeptideClear as a personal project. Something I genuinely wished existed when I started going down this rabbit hole. My main distribution channels have been LinkedIn and Reddit, which probably says something about where I am in life right now, but it's been fun.

What I didn't expect was how many people would reach out. Comments, DMs, emails, from researchers, from curious beginners, from people who've been in the space for years and just wanted a cleaner reference. It means a lot, and honestly it validates the whole premise: there's a real appetite for clarity here, not more hype. I can't understate how much the encouragement and feedback have meant, and I'm excited to keep expanding the catalog and sharing it with all of you.

Let's get into it.

If you've spent any time in fitness or longevity communities, you've seen MK-677. It goes by Ibutamoren, sometimes just "MK," and it's marketed everywhere from supplement stacks to biohacking forums. It’s a growth hormone booster you can take orally. That's a genuinely unusual claim. Most growth hormone secretagogues require injection. MK-677 doesn't. That's part of why it's so popular.

But here's what the marketing rarely tells you.

MK-677 isn't technically a peptide, it's a non-peptide ghrelin receptor agonist. It works by mimicking ghrelin (the hunger hormone) and stimulating the pituitary to release growth hormone and IGF-1. It does this. That part is real. The clinical evidence actually shows meaningful increases in GH and IGF-1 levels in humans across several studies.

The problem is what comes after that.

Most of the human studies are short-term, narrow in population (often elderly or GH-deficient patients), and almost entirely funded by the pharmaceutical industry, specifically Merck, which developed MK-677 as a potential drug for conditions like muscle wasting and osteoporosis before quietly shelving it. The drug never made it through Phase 3. The reasons matter: side effects including significant water retention, increased appetite (expected, given the ghrelin mechanism), elevated fasting glucose, and in longer studies, some concerns around insulin sensitivity.

The evidence that it does what the fitness market claims, build muscle, reduce fat, improve sleep and recovery in healthy people, is thin. The evidence that it elevates GH and IGF-1? Solid. What those elevated levels actually translate to in healthy adults over time? That's where the literature gets quiet.

This is exactly the kind of gap PeptideClear's Research Quality Score is designed to surface. More on that below.

Full profile here → https://peptideclear.com/peptides/ibutamoren

This one feels settled. Collagen is a $6 billion global market. It's in every wellness routine. The claim that it improves skin hydration, elasticity, wrinkles, is treated as basically established fact.

So what does the research actually say?

Here's where it gets interesting. A major 2025 meta-analysis published in The American Journal of Medicine looked at 23 randomized controlled trials covering 1,474 participants. When all 23 studies were pooled together, collagen supplementation did show improvements in skin hydration, elasticity, and wrinkles. Positive result.

But when the researchers ran a subgroup analysis separating industry-funded studies from independently funded ones, the picture changed entirely. The independently funded studies, the ones without a financial stake in the outcome, showed no significant effect. The positive results were driven almost entirely by pharmaceutical-funded research.

This is the exact dynamic the RQS Funding Independence dimension is built to catch. A study can be methodologically sound and still produce a biased outcome if the people funding it have a financial interest in what it finds.

The reality: the honest answer on collagen and skin is "we don't know", at least not from independent evidence. It may work. The mechanism is plausible. But the clean, confident claim you see on every collagen product is running ahead of what independent science currently supports.

Full profiles here → https://peptideclear.com/peptides/collagen-type-i

https://peptideclear.com/peptides/collagen-type-iii

Every compound in the PeptideClear catalog has an evidence grade. Human RCT, Observational, Animal Only, and so on. That tells you the type of research that exists. But it doesn't tell you how much weight to give it.

That's the problem the Research Quality Score was built to solve.

The RQS scores each compound out of 100 across 7 dimensions: study design, sample size, replication, journal impact factor, funding independence, population diversity, and lead researcher h-index. The goal is to surface not just what the research says, but how credible the research itself is.

Ibutamoren is a perfect example of why this matters. It has Human RCT evidence that sounds strong. But its RQS score reflects a different story: most of those trials are industry-funded, narrow in population, and short-term. The score captures that nuance. The evidence grade alone doesn't.

Every compound in the catalog now has a full RQS breakdown on its profile page. Take a look and let me know what you think. I'm genuinely interested in feedback on the methodology from anyone who knows this literature.

Full profiles here → https://peptideclear.com/peptides

The FDA is moving on peptides. In April, the FDA removed 12 peptides from its Category 2 restricted list and scheduled a Pharmacy Compounding Advisory Committee meeting for July 23–24 to evaluate whether to formally clear them for compounding. This is the most significant regulatory shift in the peptide space in years, though it's worth noting the July meeting is a procedural step, not an approval. Formal rulemaking could still take a year or more after that.

Psychedelics and PTSD just got a regulatory push. The FDA issued priority review vouchers to companies studying psilocybin for treatment-resistant depression and methylone (an MDMA analog) for PTSD, fast-tracking their review timelines from months to weeks. Not an approval, but a meaningful signal of where the agency's focus is heading on mental health treatment.

Given everything we covered on collagen this issue, GHK-Cu is a natural companion. It's a naturally occurring copper-binding peptide that stimulates collagen synthesis. GHK-Cu works upstream of the collagen supplement you'd take orally. The evidence base is more interesting than most skin-focused compounds: it has human RCT data, a well-documented mechanism, and a long research history going back to Dr. Loren Pickart's work. It also sits at an intersection of skin, wound healing, and hair research that makes it one of the more multidimensional entries in the catalog.

Full profile → peptideclear.com/peptides/ghk-cu

Hopefully that was helpful/interesting, see you next week.

-Emeka

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.